Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMD) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 22,109 shares, a decline of 32.4% from the March 15th total of 32,693 shares. Based on an average trading volume of 26,195 shares, the short-interest ratio is presently 0.8 days. Currently, 0.3% of the company’s shares are sold short.

Ainos Price Performance

Shares of NASDAQ AIMD opened at $1.64 on Tuesday. The firm has a market cap of $11.92 million, a PE ratio of -0.46 and a beta of 2.30. The company has a current ratio of 1.06, a quick ratio of 0.78 and a debt-to-equity ratio of 1.45. Ainos has a 1-year low of $1.26 and a 1-year high of $4.50. The company has a fifty day moving average price of $1.55 and a 200 day moving average price of $2.22.

Ainos (NASDAQ:AIMD) last announced its earnings results on Monday, March 30th. The company reported ($0.85) earnings per share for the quarter. The company had revenue of $0.01 million during the quarter. Ainos had a negative return on equity of 140.10% and a negative net margin of 11,912.10%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Ainos in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Insider Buying and Selling

In other Ainos news, major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of Ainos stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $2.17, for a total transaction of $99,820.00. Following the completion of the sale, the insider owned 989,925 shares of the company’s stock, valued at approximately $2,148,137.25. The trade was a 4.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.79% of the company’s stock.

Hedge Funds Weigh In On Ainos

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AIMD. Mariner LLC acquired a new position in Ainos in the 4th quarter worth $37,000. Two Sigma Investments LP bought a new stake in Ainos during the 3rd quarter worth about $80,000. DRW Securities LLC lifted its position in Ainos by 272.6% during the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after buying an additional 48,439 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Ainos by 13.1% during the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after buying an additional 7,700 shares in the last quarter.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.